基于弥散加权成像的影像组学列线图用于肌层浸润性膀胱癌患者术前无进展生存预测
研究纳入210例术前行DWI的肌层浸润性膀胱癌患者,用LASSO构建影像组学标签并生成列线图预测无进展生存。影像组学标签与PFS显著相关(log-rank P=0.0073)且为独立因素(P=0.0004);联合列线图C-index为0.702(95%CI 0.602,0.802),优于临床病理列线图(0.682,95%CI 0.575,0.788)和影像组学标签(0.612,95%CI 0.493,0.731),NRI为0.226(95%CI 0.016,0.415,P=0.038)。
要点
- 基于DWI的影像组学标签是肌层浸润性膀胱癌患者PFS的独立预测因素(P=0.0004)。
- 联合影像组学标签、临床分期及其他临床病理因素的列线图预测PFS的C-index为0.702(95%CI 0.602,0.802)。
- 影像组学列线图较临床病理列线图有更好的校准和分类(NRI=0.226,95%CI 0.016,0.415,P=0.038)。
核心结论
- 基于DWI的影像组学标签是MIBC患者PFS的独立预测因素。
- 联合影像组学标签、临床分期和其他临床病理因素在个体PFS预测中取得更好性能。
研究设计与样本
- 研究纳入210例术前行DWI的MIBC患者。
- 采用LASSO模型构建影像组学标签,并生成影像组学列线图。
- 以C-index评价区分度,计算NRI评价重分类改善,决策曲线分析评价临床有用性。
诊断标准与关键数值
- 影像组学标签与PFS显著相关(log-rank P=0.0073),且为独立预测因素(P=0.0004)。
- 影像组学列线图C-index为0.702(95%CI 0.602,0.802),临床病理列线图为0.682(95%CI 0.575,0.788),影像组学标签为0.612(95%CI 0.493,0.731)。
- NRI为0.226(95%CI 0.016,0.415,P=0.038)。
临床应用与阅片要点
- 作者认为,联合影像组学标签、临床分期和其他临床病理因素可取得更好的个体PFS预测性能。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: To develop a radiomics signature using diffusion-weighted imaging (DWI) for predicting progression-free survival (PFS) in muscle-invasive bladder cancer (MIBC) patients and to assess its incremental value over traditional staging system.
METHOD: 210 MIBC patients undergoing preoperative DWI were enrolled. A radiomics signature was built using LASSO model. A radiomics nomogram was generated to assess the incremental value of the radiomics signature over existing risk factors in PFS estimation in terms of calibration, discrimination, reclassification and clinical usefulness. Kaplan-Meier analysis was used to assess the association of the radiomics signature with PFS. C-index was used as a discrimination measure. Net reclassification improvement (NRI) was calculated to evaluate the usefulness improvement added by the radiomics signature. Decision curve analysis was performed to evaluate the clinical usefulness of the nomograms.
RESULTS: The radiomics signature was significantly associated with PFS (log-rank P = 0.0073) and was independent with clinicopathological factors (P = 0.0004). The radiomics nomogram achieved better performance in PFS prediction (C-index: 0.702, 95 % confidence interval [CI]: 0.602, 0.802) than either clinicopathological nomogram (C-index: 0.682, 95 % CI: 0.575, 0.788) or radiomics signature (C-index: 0.612, 95 % CI: 0.493, 0.731), and achieved better calibration and classification (NRI: 0.226, 95 % CI: 0.016, 0.415, P = 0.038). Decision curve analysis demonstrated the better clinical usefulness of the radiomics nomogram.
CONCLUSIONS: The DWI-based radiomics signature was an independent predictor of PFS in MIBC patients. Combining the radiomics signature, clinical staging and other clinicopathological factors achieved better performance in individual PFS prediction.
引用
- Zhang S, Song M, Zhao Y, et al. Radiomics nomogram for preoperative prediction of progression-free survival using diffusion-weighted imaging in patients with muscle-invasive bladder cancer. Eur J Radiol. 2020. PMID: 32905953. doi:10.1016/j.ejrad.2020.109219
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。